Medtronic 2026 Q2 Earnings Revenue and Net Income Grow 6.6% and 8.1%

Medtronic (MDT) reported fiscal 2026 Q2 earnings on Nov 25, 2025, delivering results that exceeded expectations. The company beat quarterly EPS estimates by $0.05 and raised FY2026 guidance to $5.62–$5.66 per share, reflecting confidence in sustained growth.

Revenue

Medtronic’s total revenue rose 6.6% year-over-year to $8.96 billion, driven by robust performance across its core segments. Cardiovascular led with $3.44 billion, followed by Neuroscience at $2.56 billion and Medical Surgical at $2.17 billion. The Diabetes segment contributed $757 million, while Other revenue accounted for $35 million. This diversified growth underscores the company’s resilience in key markets.

Earnings/Net Income

Earnings per share (EPS) increased 8.1% to $1.07, with net income reaching $1.38 billion—8.1% higher than the prior year. The company’s profitability remains stable, supported by 13 consecutive years of positive Q2 net income. This growth highlights Medtronic’s operational efficiency and market leadership.

Price Action

MDT shares gained 1.49% in the latest trading day, 4.51% over the week, and 12.47% month-to-date, reflecting investor optimism despite mixed post-earnings performance.

Post-Earnings Price Action Review

The strategy of buying MDT when earnings beat and holding for 30 days resulted in a total return of -16.80%, significantly underperforming the benchmark’s 117.59%. While the approach showed no capital losses (maximum drawdown of 0.00%), it lagged the market with a Sharpe ratio of -0.15 and a CAGR of -3.25%.

CEO Commentary

Medtronic’s CEO, Geoff Martha, emphasized the company’s strong operational execution and long-term strategic focus on innovation and market expansion.

Guidance

The firm reaffirmed FY2026 EPS guidance of $5.62–$5.66, slightly above the sell-side consensus of $5.46, signaling confidence in its ability to navigate macroeconomic challenges.

Additional News

Recent developments include insider transactions and institutional activity. Denise L. Blomquist, a Medtronic officer, gifted 170 shares on Nov 20, 2025, while EVP Harry Skip Kiil sold 8,605 shares in September, reducing his stake by 19.46%. Institutional investors also adjusted holdings: Vestor Capital LLC slashed its stake by 94.9% in Q2, retaining 2,700 shares, and Fiducient Advisors LLC acquired 3,033 new shares. Analysts have upgraded MDT to “Overweight” and raised price targets, with a consensus rating of “Moderate Buy” and a $109.72 average target.